World Health Organization Sounds Concern Over Critical Scarcity of Weight-Loss Jabs
Under 10% of individuals eligible to benefit from weight-loss injections like Wegovy have access to them, states the World Health Organization as it publishes its initial guidance on the drugs.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for more widespread and fairer availability to GLP-1 medication.
Based on projections, over two billion could be obese by 2030 if no action is taken.
"Our new guidelines recognises that obesity is a lifelong illness that can be treated with holistic and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are key obstacles to universal availability to the treatments that can help people shift considerable weight, explains the body.
Skinny Jab Scarcity
Even in the current most optimistic outlook, the production of such drugs would only suffice for approximately 100 million people – fewer than 10% of the global need, according to the WHO.
The guideline encourages countries and companies to expand availability, via approaches including licensing agreements.
Exclusive production rights on semaglutide – the main ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026.
How Weight-Loss Jabs Function
The injections replicate a biological compound to reduce digestion speed, reduce hunger and boost satiety so people reduce food intake.
Individuals commonly see weight reduction after several weeks of commencing the once-weekly jabs.
Studies points to people may put most of the weight back on within a year of discontinuing the medication, when their typical appetite come back.
To be above a healthy weight increases your likelihood for contracting diseases, such as diabetes, heart disease, stroke, and certain cancers.
Excess weight impacts people in all nations and was associated with millions of fatalities worldwide in 2024, per the health agency.
